Pictet Asset Management (Switzerland)’s Royalty Pharma RPRX Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$21.7M	Buy	706,952 +128,674	+22%	+$4.36M	0.03%	442
2023 Q1	$20.8M	Buy	578,278 +363,524	+169%	+$13.5M	0.03%	449
2022 Q4	$8.49M	Buy	214,754 +23,498	+12%	+$981K	0.01%	627
2022 Q3	$7.68M	Buy	191,256 +75,538	+65%	+$3.23M	0.01%	638
2022 Q2	$4.87M	Sell	115,718 -1,675	-1%	-$68.7K	0.01%	760
2022 Q1	$4.57M	Buy	117,393 +1,775	+2%	+$69.7K	0.01%	827
2021 Q4	$4.61M	Buy	115,618 +55,753	+93%	+$2.17M	﹤0.01%	852
2021 Q3	$2.16M	Buy	+59,865	New	+$2.33M	﹤0.01%	988

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s RPRX Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) increased its Royalty Pharma (RPRX) stake by 22% in Q2 2023, buying an estimated $4.36M and bringing the position to 706,952 shares worth $21.7M. The position accounts for 0.03% of the portfolio, ranked #442.

Pictet Asset Management (Switzerland) first reported a position in RPRX in Q3 2021 and has held it in 8 quarters since. 326 funds tracked by Wall St. Rank hold RPRX as of Q2 2023.

Pictet Asset Management (Switzerland) held 706,952 shares of Royalty Pharma worth $21.7M as of Q2 2023.
Pictet Asset Management (Switzerland) bought 128,674 Royalty Pharma shares in Q2 2023, an estimated $4.36M.
Royalty Pharma made up 0.03% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #442 holding.
Pictet Asset Management (Switzerland) first reported a position in Royalty Pharma in Q3 2021 and has held it in 8 quarters since.
326 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.